Hematological Disease Biospecimens: Tracking Clonal Evolution Through Serial Sampling

Hematological cancers and disorders offer a unique research opportunity, because the diseased tissue is accessible through a simple blood draw. This allows for longitudinal sampling that just isn’t possible with solid tumors, which require invasive biopsies. Leukemias, lymphomas, myelomas, and myelodysplastic syndromes all arise from blood stem and progenitor cells that circulate continuously through peripheral blood. Malignant cells can make up anywhere from 5–95% of white blood cells, depending on the disease stage and treatment.[1]

This easy access supports serial biospecimen collection that tracks how a disease evolves — from diagnosis through treatment, remission, and possible relapse. That kind of detailed timeline reveals dynamic processes like clonal selection, the emergence of drug resistance, and lingering minimal residual disease.

Clonal evolution theory holds that cancers progress by picking up genetic changes one after another. Each change gives the cell a survival advantage, so successful subclones outcompete their predecessors.[2] In hematological cancers, this plays out over months to years. Serial Human Whole Blood and Human PBMCs collections capture these changes in fine detail.

Single-cell sequencing on samples collected over time can reconstruct family trees showing how one clone descended from another. It can also identify the mutations driving that change and reveal how resistance to treatment develops.[3] These insights shape treatment strategy, suggest drug combinations that prevent resistance, and support early relapse detection through minimal residual disease monitoring.

At Sanguine, our direct-to-donor model across the United States allows flexible serial collection wherever patients get care — academic centers, community oncology practices, or home-based phlebotomy. Our longitudinal programs support monthly, quarterly, or event-driven collections spanning years. These produce Human PBMCs, Human Plasma, Human Serum, Human Leukopak, and cell-type isolations including Human CD3+ T Cells and Human CD19+ B Cells from every timepoint. Detailed genomic annotation — treatment history, response assessments, clinical outcomes — supports retrospective analysis from study design to receipt of samples.

Serial Sampling Strategies for Clonal Evolution Studies

How often you sample determines how much evolutionary detail you can see. Weekly collections reveal fast-moving clonal changes during intensive therapy, while quarterly sampling is enough for chronic diseases that progress more slowly.

Acute myeloid leukemia (AML) shows dramatic clonal shifts during induction chemotherapy, as founding clones decline rapidly while minor subclones expand within days to weeks.[4] Capturing this window takes weekly or bi-weekly Human Whole Blood collections during active treatment, though practical limits often narrow sampling to diagnosis, post-induction, and relapse. Chronic lymphocytic leukemia (CLL) progresses more slowly — annual collections document its evolution over decades before treatment starts, with quarterly sampling once therapy begins.

Optimal Timepoint Selection for Hematological Studies:

• Diagnosis (pre-treatment baseline establishing founding clone genetics)
• During induction therapy (weekly or bi-weekly when feasible, capturing treatment-induced selection)
• Post-induction or post-consolidation (documenting treatment response and residual disease)
• Maintenance therapy (quarterly monitoring for emerging resistance or relapse)
• Relapse or progression (comparing evolved clones to diagnosis establishing resistance mechanisms)
• Post-transplant monitoring (monthly during first year when graft-versus-leukemia effects operate)
• Long-term follow-up (annual collections documenting clonal evolution in remission)
• Event-driven collections during complications, infections, or secondary malignancies

Event-driven collections add to scheduled sampling by capturing important transitions — a treatment change, progression, remission, or a complication. These priority collections are often more informative than scheduled timepoints, since they document selective pressures and how a clone responds to a specific intervention.[5] Unscheduled collections need collection teams and processing to move fast. That’s why Sanguine maintains a nationwide mobile phlebotomy network that delivers a processed specimen 48–72 hours after a request.

Sample volume needs vary by platform. Whole exome sequencing needs 1–5 µg of genomic DNA, which you can get from 10 mL of Human Whole Blood. Single-cell RNA sequencing typically analyzes 5,000–10,000 cells from 10–30 mL of blood, depending on white cell counts.[6] Patients with a high leukemic burden provide plenty of material; patients in remission with minimal residual disease need larger volumes, or enrichment, to isolate rare malignant cells. Human Leukopak collections over 100 mL support dozens of applications while banking extra material for future analysis.

Treatment-naive diagnostic specimens mark the evolutionary starting point, documenting the founding clone’s genetics before therapy reshapes the picture. These “time zero” specimens let researchers retrospectively identify pre-existing resistance mutations present at low frequencies. These are mutations that bulk sequencing would miss, but deep or single-cell methods can reveal.[7] Minor subclones carrying resistance mutations often expand under treatment, and their trajectory is often predictable from the subclonal makeup at diagnosis. Banking enough diagnostic material lets researchers keep re-examining samples as new resistance mechanisms or prognostic markers emerge.

Technological Approaches to Clonal Evolution Analysis

Bulk Sequencing Methods

Whole exome sequencing (WES) identifies protein-coding mutations that distinguish malignant clones from normal blood cell production. Researchers do this by comparing them to matched germline DNA from skin biopsies or CD3+ T cells. Standard WES detects mutations present in 5–10% or more of cells, capturing dominant clones and major subclones but potentially missing rarer populations.[8] Because it’s cost-effective, WES works well for routine use on samples collected over time. Variant allele frequencies track clonal changes across timepoints — rising frequencies signal expansion, falling frequencies suggest response to treatment or immune clearance.

Targeted deep sequencing panels that focus on frequently mutated genes can detect variants at 0.1–1% frequency, thanks to very high coverage (10,000–50,000x per base).[9] Panels covering 50–300 genes allow cost-effective monitoring of known mutations while still catching additional hotspot changes. This targeted approach supports monitoring many samples per patient while using less material — critical for banked collections where material can’t be replaced.

Minimal residual disease (MRD) monitoring by deep sequencing detects malignant cells that persist below what a microscope can see (under 1% of nucleated cells). MRD positivity after induction therapy strongly predicts relapse risk across multiple cancers, and MRD-negative patients tend to do better.[10] Personalized MRD assays, designed around each patient’s founding mutations, can detect one cell in 100,000. Serial Human Whole Blood or Human PBMC collections at monthly intervals support MRD tracking that can predict relapse months before it shows up clinically.

Single-Cell Approaches

Single-cell DNA sequencing reconstructs a tumor’s family tree in fine detail. It assigns individual cells to a clonal lineage based on shared mutations and figures out the order mutations were acquired.[11] It reveals branching patterns where multiple subclones coexist, measures how diverse the subclones are, and identifies rare resistant populations. Used repeatedly over time, it tracks clones expanding and shrinking and documents when clones die out under treatment. It also reveals cases where separate clones independently evolve the same resistance mutation.

Single-cell RNA sequencing (scRNA-seq) adds to genomic analysis by profiling transcriptional states — proliferation rates, differentiation states, and which pathways are active. The same mutation can produce different outcomes depending on cellular context, and scRNA-seq can tell apart functionally distinct states within genetically identical clones.[12] Applied to serial Human PBMCs, it tracks both genetic evolution and shifts in cell behavior, revealing treatment-induced changes in differentiation or dormancy that come before genetic resistance appears.

Multi-omic single-cell approaches profile DNA mutations, RNA expression, and surface proteins from the same individual cells at once, combining information that would be impossible to gather separately.[13] This links specific mutations to cell behavior — for example, mutations that activate the RAS pathway produce a distinctive gene expression pattern that shows up before any visible transformation. Our Human Leukopak products provide the cell counts (50,000–100,000 cells per sample per timepoint) that thorough single-cell multi-omics needs.

Disease-Specific Evolutionary Patterns

Acute Myeloid Leukemia

AML shows fast clonal changes, with founder clones dominant at diagnosis, then shifting dramatically during therapy. Induction chemotherapy creates intense selection pressure that favors resistant subclones, with common mechanisms including TP53 mutations, RAS pathway activation, and chromatin-remodeling gene fusions.[14] Sampling every 1–2 weeks during induction reveals these shifts in real time, and Human Whole Blood is enough for repeated genomic profiling. Post-remission collections identify leftover cell populations that can regrow into a relapse months later, detectable at frequencies below 0.1%.

AML Serial Sampling Protocol:

• Pre-treatment diagnosis (30–50 mL blood for comprehensive multi-platform analysis)
• Day 14 post-induction (bone marrow aspiration + 10 mL blood)
• Day 28 post-induction response assessment (20 mL blood)
• Pre-consolidation (10 mL blood)
• Post-consolidation cycles (10 mL blood each)
• Monthly MRD monitoring during remission (10 mL blood)
• At relapse if occurs (30 mL blood comparing to diagnosis)
• Allogeneic transplant recipients: weekly first month, monthly ongoing

Chronic Lymphocytic Leukemia

CLL typically progresses slowly over years to decades before treatment starts. Quarterly or annual collections document its gradual evolution and the buildup of high-risk changes like TP53 mutations, NOTCH1 mutations, or complex chromosome abnormalities. But CLL can also show long periods of stability suddenly interrupted by rapid clonal expansion.[15] These sudden shifts often coincide with Richter transformation into an aggressive lymphoma, or treatment-resistant disease. Our Human PBMCs from untreated CLL patients show median purities above 70% lymphocytes, with malignant B cells identifiable by CD5+CD19+ markers.

CLL Longitudinal Collection Strategy:

• Diagnosis (30 mL for banking given years before treatment likely)
• Annually during watch-and-wait (10 mL each, tracking clonal evolution)
• Upon treatment initiation (20 mL pre-treatment)
• Quarterly during active therapy (10 mL monitoring response)
• Annually during long-term follow-up post-therapy
• Immediately if Richter transformation suspected (30 mL)

Myelodysplastic Syndromes

MDS are blood cancers marked by ineffective blood cell production, low blood counts, and a variable risk of progressing to AML. The clonal makeup at diagnosis predicts that risk — patients with multiple clones progress to AML more often than those with one dominant clone.[16] Serial Human Whole Blood and Human Leukopak collections every 3–6 months document clonal evolution, identifying high-risk clones as they expand months before AML shows up under a microscope. TP53-mutant clones are especially linked to treatment resistance and poor outcomes, and serial deep sequencing can catch these early expansions in time for preemptive treatment.

Multiple Myeloma

Myeloma’s clonal evolution happens in bone marrow plasma cells rather than peripheral blood, which complicates longitudinal sampling since bone marrow aspirations are more invasive than a blood draw. But in advanced disease, circulating plasma cells do enter the bloodstream, allowing Human Whole Blood monitoring once flow cytometry confirms there are enough circulating cells.[17] Cell-free DNA shed from bone marrow plasma cells also circulates in Human Plasma, enabling liquid biopsy tracking of myeloma-specific mutations without repeated bone marrow procedures. Serum M-protein levels from Human Serum give a standard measure of disease activity.

Immune Microenvironment Dynamics

Hematological cancers evolve inside complex immune environments, where malignant cells try to evade surveillance while normal immune cells try to eliminate them. T cells that target tumor-associated antigens create selective pressure that favors immune evasion — antigen loss, reduced MHC expression, and immune-suppressing cytokine production.[18] Serial flow cytometry on Human PBMCs tracks immune changes alongside clonal evolution, revealing exhausted T cell markers (PD-1, TIM-3, LAG-3) building up as the disease progresses.

Key Immune Populations to Track Longitudinally:

• Regulatory T cells (CD4+CD25+FOXP3+) suppressing antitumor immunity
• Exhausted CD8+ T cells (PD-1+TIM-3+) with impaired cytotoxic function
• Activated NK cells (CD56+CD16+) mediating tumor surveillance
• Myeloid-derived suppressor cells (MDSCs) inhibiting immune responses
• Tumor-infiltrating lymphocytes (when bone marrow available)
• Plasma cytokines including IL-6, IL-10, TGF-β shaping immune environments

Immunotherapy causes dramatic clonal shifts, as treatment activates an immune attack on malignant clones. Checkpoint inhibitors that block PD-1 or CTLA-4 reverse T cell exhaustion, restoring the immune surveillance that can eliminate previously dominant clones.[19] CD19 CAR T cell therapies wipe out B cell cancers but select for CD19-negative cells that escape treatment. That resistance can be caught with serial flow cytometry on Human PBMCs months before a clinical relapse shows up. Pairing serial immune profiling with clonal evolution tracking shows whether resistance comes from genetic evolution or immune escape. That distinction helps decide whether the next treatment should target a different antigen or activation strategy.

Practical Considerations for Serial Collection Programs

Whether a longitudinal study succeeds depends on patient compliance, and collection burden directly affects how many patients stay in the study. Minimizing travel with home-based phlebotomy, coordinating research draws with clinical visits, and clearly explaining the research’s value all improve retention.[20] Financial compensation for time and discomfort recognizes participants’ contributions while staying ethically appropriate. Sanguine’s nationwide mobile phlebotomy network allows collection wherever patients prefer — home, workplace, or clinic.

Strategies Maximizing Longitudinal Study Retention:

• Flexible scheduling accommodating patient availability
• Mobile phlebotomy eliminating travel requirements
• Coordination with clinical blood draws minimizing needle sticks
• Regular communication maintaining engagement between collections
• Results sharing when appropriate and IRB-approved
• Annual newsletters describing study progress and scientific impact
• Appropriate compensation respecting participant time
• Streamlined consent allowing remote enrollment
• Text or email appointment reminders
• Backup collection windows if patients miss scheduled appointments
• Clear communication of study duration and expected visits
• Participant advisory boards providing input into protocol design

Standardizing how samples are processed matters most when comparing samples collected months apart, at different sites, or by different staff. Standard operating procedures that specify tubes, processing timing, centrifugation settings, and freezing steps keep technical variation from being mistaken for real biological change.[21] The time between the blood draw and freezing especially affects cell viability and gene expression, since delays trigger stress responses that alter how cells look. Sanguine’s processing labs across the United States support under-24-hour turnaround from collection to freezing, even for remote patients.

Managing inventory for longitudinal studies means tracking dozens to hundreds of aliquots per patient across many timepoints, with database systems linking each sample to clinical data. Many studies run 5–10 years, and researchers often access specimens years after they were first banked.[22] Detailed records — collection dates, processing methods, storage locations, freeze-thaw history, remaining volume — let researchers pick the best specimen for a new question while preserving material that can’t be replaced.

Analytical Workflows Integrating Multi-Timepoint Data

Phylogenetic Tree Reconstruction

Computational methods reconstruct a clone’s family tree from sequencing data collected across multiple samples, inferring which clone descended from which and the order mutations were acquired. These family trees reveal whether evolution happens in a straight line, with one clone replacing the next, or through branching, with multiple lineages existing side by side.[23] Trunk mutations, present in every sample, likely happened early and could be good targets since hitting them would eliminate every descendant clone. Branch mutations that show up later make less attractive targets, since treating one branch leaves the others untouched.

Tools including CITUP, PyClone, and PhyloWGS infer clonal family trees from bulk sequencing variant frequencies, while single-cell methods including SCITE and OncoNEM work directly from single-cell genotype data.[24] These tools account for sequencing errors, contamination from normal cells, and changes in chromosome copy number. Combining data from multiple timepoints improves these family trees compared to analyzing a single sample alone, since the order events happened in rules out implausible paths.

Longitudinal Trajectory Analysis

Time-course analyses identify which genes’ mutations consistently expand or shrink across a group of patients, revealing recurring drivers of progression or resistance. Mixed-effects statistical models account for differences between patients while still spotting consistent trends, separating random drift from changes driven by selection.[25] These population-level analyses complement single-patient family trees, revealing evolutionary patterns that hold true more broadly.

Machine learning models trained on early-timepoint data can forecast likely disease trajectories and relapse risk. These models combine baseline clonal makeup, mutation profiles, treatment regimens, and clinical factors.[26] Testing these predictions against what actually happens at later timepoints checks their accuracy. Successful models could eventually support choosing treatment for a patient before resistance even develops.

Check Our Inventory

Ready to launch your longitudinal hematological disease research?

Sanguine’s comprehensive specimen menu supports serial collections from diagnosis through treatment and long-term follow-up. Our Human PBMCs, Human Plasma, Human Leukopak, and specialized isolations enable multi-platform clonal evolution studies from study design to receipt of samples.

Request a Custom Quote →

Ethical Sourcing and Regulatory Compliance

All Sanguine biospecimens are collected under IRB-approved protocols with thorough informed consent. Our HIPAA-compliant systems protect privacy while still supporting detailed genomic annotation. We maintain ISO 9001:2015 and ISO 13485:2016 certifications demonstrating quality management across operations. Donor compensation follows ethical guidelines, and geographic diversity in our network across the United States advances health equity. Specimens are designated Research Use Only (RUO) with clear documentation.

References

1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-1152. doi:10.1056/NEJMra1406184
2. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306-313. doi:10.1038/nature10762
3. Morita K, Wang F, Jahn K, et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020;11(1):5327. doi:10.1038/s41467-020-19119-8
4. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506-510. doi:10.1038/nature10738
5. Rampal R, Ahn J, Abdel-Wahab O, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci USA. 2014;111(50):E5401-E5410. doi:10.1073/pnas.1407792111
6. Paguirigan AL, Smith J, Meshinchi S, et al. Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia. Sci Transl Med. 2015;7(281):281re2. doi:10.1126/scitranslmed.aaa0763
7. Shlush LI, Mitchell A, Heisler L, et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature. 2017;547(7661):104-108. doi:10.1038/nature22993
8. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074. doi:10.1056/NEJMoa1301689
9. Kennedy SR, Schmitt MW, Fox EJ, et al. Detecting ultralow-frequency mutations by duplex sequencing. Nat Protoc. 2014;9(11):2586-2606. doi:10.1038/nprot.2014.170
10. Short NJ, Kantarjian H, Ravandi F, Daver N. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther Adv Hematol. 2019;10:2040620719827310. doi:10.1177/2040620719827310
11. Kim C, Gao R, Sei E, et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell. 2018;173(4):879-893.e13. doi:10.1016/j.cell.2018.03.041
12. van Galen P, Hovestadt V, Wadsworth Ii MH, et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell. 2019;176(6):1265-1281.e24. doi:10.1016/j.cell.2019.01.031
13. Rattray NJW, Hamrang Z, Trivedi DK, et al. Metabolic dysregulation in vitamin E and carnitine shuttle energy mechanisms associate with human frailty. Nat Commun. 2019;10(1):5027. doi:10.1038/s41467-019-12716-2
14. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264-278. doi:10.1016/j.cell.2012.06.023
15. Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525-530. doi:10.1038/nature15395
16. Makishima H, Yoshizato T, Yoshida K, et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet. 2017;49(2):204-212. doi:10.1038/ng.3742
17. Lohr JG, Kim S, Gould J, et al. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med. 2016;8(363):363ra147. doi:10.1126/scitranslmed.aac7037
18. Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687-692. doi:10.1158/1078-0432.CCR-14-1860
19. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355. doi:10.1126/science.aar4060
20. Treweek S, Pitkethly M, Cook J, et al. Strategies to improve recruitment to randomised trials. Cochrane Database Syst Rev. 2018;2(2):MR000013. doi:10.1002/14651858.MR000013.pub6
21. Betsou F, Gunter E, Clements J, et al. Identification of evidence-based biospecimen quality-control tools. Biopreserv Biobank. 2013;11(2):110-118. doi:10.1089/bio.2012.0053
22. Henderson GE, Cadigan RJ, Edwards TP, et al. Characterizing biobank organizations in the U.S. J Biorepository Sci Appl Med. 2013;2013(1):3-12. doi:10.2147/BSAM.S37942
23. Kuipers J, Jahn K, Raphael BJ, Beerenwinkel N. Single-cell sequencing data reveal widespread recurrence and loss of mutational hits in the life histories of tumors. Genome Res. 2017;27(11):1885-1894. doi:10.1101/gr.220707.117
24. Jahn K, Kuipers J, Beerenwinkel N. Tree inference for single-cell data. Genome Biol. 2016;17:86. doi:10.1186/s13059-016-0936-x
25. Williams MJ, Werner B, Barnes CP, et al. Identification of neutral tumor evolution across cancer types. Nat Genet. 2016;48(3):238-244. doi:10.1038/ng.3489
26. Acar A, Nichol D, Fernandez-Mateos J, et al. Exploiting evolutionary steering to induce collateral drug sensitivity in cancer. Nat Commun. 2020;11(1):1923. doi:10.1038/s41467-020-15596-z